Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

GSK builds oncology pipeline as drug shown to help myeloma patients

GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.

Read More »

Novartis’ Kisqali Effective in Postmenopausal Women with Breast Cancer

Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.

Read More »

Merck’s Keytruda Hits Another Endpoint, This Time in Triple-Negative Breast Cancer

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in combination with chemotherapy hit the primary endpoint in the company’s Phase III KEYNOTE-522 in triple-negative breast cancer.

Read More »

European Commission Approves Talzenna for Patients with Inherited BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

The European Commission approved Pfizer Inc.’s Talzenna (talazoparib), an oral polypolymerase inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene 1/2-mutations who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer.

Read More »

FDA Approves Amgen and Allergan’s Kanjinti

Amgen Inc. and Allergan plc announced that the U.S. FDA approved Kanjinti (trastuzumab-anns) for all approved cancer indications of the reference product Herceptin.

Read More »

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

Novartis released data showing sharply improved overall survival rates for the breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance.

Read More »

Novartis’ breast cancer treatment wins FDA approval

The FDA approved Novartis AG’s Piqray in combination with a hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer.

Read More »

Merck’s Keytruda fails as monotherapy in breast cancer study

Merck & Co. Inc.’s blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.

Read More »

Puma’s Nerlynx Edges Out Novartis’ Tykerb in Breast Cancer Trial

Puma Biotechnology’s Nerlynx (neratinib), in combination with Roche’s chemotherapy drug Xeloda (capecitabine), showed a treatment advantage compared to Novartis’ Tykerb (lapatinib) and Xeloda in a Phase III breast cancer study.

Read More »

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan’s Daiichi Sankyo’s met the main goal in a mid-stage study, bolstering the companies’ position in a highly competitive oncology market.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom